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Abstract
Background: The determination of coronary flow reserve (CFR) is an essential concept at the moment of decision-
making in ischemic heart disease. There are several direct and indirect tests to evaluate this parameter. In this
sense, dobutamine stress echocardiography is one of the pharmacological method most commonly used
worldwide. It has been previously demonstrated that CFR can be determined by this technique. Despite our wide
experience with dobutamine stress echocardiography, we ignored the necessary heart rate to consider sufficient
the test for the analysis of CFR. For this reason, our main goal was to determine the velocity of coronary flow in
each stage of dobutamine stress echocardiography and the heart rate value necessary to double the baseline
values of coronary flow velocity in the territory of the left anterior descending (LAD) coronary artery.
Methods: A total of 33 consecutive patients were analyzed. The patients included had low risk for coronary artery
disease. All the participants underwent dobutamine stress echocardiography and coronary artery flow velocity was
evaluated in the distal segment of LAD coronary artery using transthoracic color-Doppler echocardiography.
Results: The feasibility of determining CFR in the territory of the LAD during dobutamine stress echocardiography
was high: 31/33 patients (94%). Mean CFR was 2.67 at de end of dobutamine test.
There was an excellent concordance between delta HR (difference between baseline HR and maximum HR) and
the increase in the CFR (correlation coefficient 0.84). In this sense, we found that when HR increased by 50 beats,
CFR was ≥ 2 (CI 93-99.2%). In addition, 96.4% of patients reached a CFR ≥ 2 (IC 91.1 - 99%) at 75% of their
predicted maximum heart rate.
Conclusions: We found that the feasibility of dobutamine stress echocardiography to determine CFR in the
territory of the LAD coronary artery was high. In this study, it was necessary to achieve a difference of 50 bpm
from baseline HR or at least 75% of the maximum predicted heart rate to consider sufficient the test for the
analysis of CFR.
Background
Coronary atherosclerosis is a highly prevalent disease in
our population, and not just the expression of an ana-
tomic condition [1]. The functional status of this affec-
tion should be thoroughly analyzed. The valuable
information provided by coronary angiography is not
enough to study the functional status of atherosclerotic
disease [2]. In these sense, several studies have demon-
strated that management of coronary artery disease
based on coronary artery anatomy without considering a
functional approach is not superior to medical treatment
[3]. Determination of coronary flow reserve (CFR) has
been validated and supported by several trials studying
coronary artery function [4]. In patients with known
or suspected CAD stress echocardiography by semi-
simultaneous analysis of wall motion and CFR provides
critical diagnostic and prognostic information [4,6].
The use of dobutamine stress test as an alternative to
exercise testing started in 1984 [7] and its indication has
increased exponentially during the last 10 years [8].
Nowadays, dobutamine stress echocardiography is one
of the pharmacological tests most used in stress-echo
laboratories around the world [9]. The assessment of
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been studied during the last years [10,11]. In this sense,
CFR measured by this test has been compared to CFR
measured by adenosine stress echocardiography, (adeno-
sine is considered the best vasodilator stimulus to deter-
mine CFR), and has been validated in comparative
studies [11]. After reviewing the published literature,
and as we did not find any parameter indicating when
coronary flow reserve should be measured during dobu-
tamine stress echocardiography, we decided to conduct
out own investigation. According to previous studies
and to our personal experience, coronary flow velocity
has a close relation with heart rate; thus, we focused on
analyzing coronary blood flow velocity and CFR in each
stage of dobutamine stress echocardiography in order to
determine:
1- The target HR for each patient to reach a CFR ≥
2 (considered the adequate limit to rule out signifi-
cant coronary stenosis in the territory of the LAD
coronary artery by the international literature and
our own experience) [11-13] and, with this informa-
tion, to determine the delta HR and the percentage
of maximum predicted heart rate that should be
reached to make another determination of CFR.
2- The feasibility of the test.
Objetives
The goal of the present study was to determine at which
value of heart rate, CFR should be measured during
stress echocardiography. Thus, we evaluated the velocity
in the LAD coronary artery in each stage of dobutamine
stress echocardiography using transthoracic Doppler
echocardiography, in order to find:
1- The delta heart rate and the percentage of maximum
predicted heart rate that should be reached to determine
CFR during dobutamine stress echocardiography.
2- The feasibility of estimating CFR during dobuta-
mine stress echocardiography.
Methods
Study population
We prospectively included 33 patients without history of
heart disease and low pre-test probability of coronary
artery disease, who were referred to the echo-laboratory
with indication of dobutamine stress echocardiography.
Patients at high risk of coronary artery disease, history
of ischemic heart disease, moderate to severe valvular
heart disease, cardiomyopathy, left ventricular dysfunc-
tion and regional wall motion abnormalities were
excluded. Also, cases with positive test results or CFR
that did not reach the normal predetermined value (≥ 2)
were not included in the analysis. Beta blockers were
withdrawn 24 hours before the study. All participants
gave informed consent before examinations. Table 1
describes the general characteristics of the population.
Methodology of study of the LAD coronary artery
The echocardiographic procedure was performed using
two ultrasound systems, an ATL HDI-5000 Ultrasound
System with a frequency of 4-7 MHz (Doppler fre-
quency: 4 MHz) and a 2- 4 MHz matrix array transdu-
cer (Vivid 7, GE).
In color Doppler flow mapping, velocity range was set
at an average Nyquist limit of 19.2 cm/s and, when
heart rate increased, the Nyquist scale was adjusted at
higher limit for a better visualization of the LAD flow.
The color gain was adjusted to provide optimal
images, setting the color-write priority threshold above
the tissue grey-scale gain in order to identify color
blood flow in the LAD coronary artery. The anatomical
position of the LAD running along the interventricular
groove, a few centimeters beneath the surface of the
skin, provides an excellent opportunity for its visualiza-
tion and study.
With the patient in the left lateral decubitus position,
the left ventricle was imaged in the low parasternal
long-axis section, and the ultrasound beam was then
tilted clockwise until the right ventricle disappeared and
the interventricular groove was visualized with the mid-
portion of the LAD. The distal LAD can be explored
from the modified apical 3-chamber view.
The LAD coronary artery was visualized as a tubular
red structure 2-4 mm long along the anterior interven-
tricular groove, with a flow directed towards the apex
(and transducer), generating a Doppler waveform above
the baseline. Flow velocity was measured using pulsed
Doppler echocardiography with a 2-3 mm sample
volume wide, generating a typical biphasic pattern, with
a smaller systolic component and a larger diastolic one.
The long axis sections were carefully adjusted to mini-
mize the angle between the Doppler beam and the LAD
flow; we did not perform angle correction to calculate
Table 1 Basal characteristics of the population
Patients Total %
Mean age 62.1 ± 9.2 years
Men 12 36%
Diabetes 6 18%
Current smoking 7 21%
Hypertension 19 57%
Dyslipemia 10 30%
Reasons for ordering the study:
Chest pain 12 36%
Preoperative 4 12%
Diagnosis of coronary artery disease 9 27%
Other 8 24%
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numerator and denominator of the equation, without
changing the final results. We measured the flow velo-
city from the same position at each stage of dobutamine
stress echocardiography.
Coronary flow reserve was calculated as the ratio
between peak diastolic flow velocity and baseline diasto-
lic flow velocity; final values of flow velocity represented
an average of 3 cardiac cycles.
Statistical Analysis
Continuous variables were expressed as mean and stan-
dard deviation and categorical variables as percentage.
The association between variables was evaluated using
Pearson’s correlation coefficient. All calculations were
performed using MedCalc statistical software.
Study Protocol
All patients underwent complete color Doppler echocar-
diography. Digital images were obtained for wall motion
analysis following conventional dobutamine stress echo-
cardiography protocol. Diastolic velocities in the LAD
coronary artery were measured during each stage. The
hemodynamic variables - heart rate and blood pressure
- were monitored. Dobutamine was administered by
infusion pump in all patients. We did not use any con-
trast enhancement agent. Dobutamine infusion started
at 5mcg/kg/min and increased in 3-minute stages to 10,
20, 30, 40 and 50 mcg/kg/min or until target heart rate
was attained. Intravenous atropine was given (0.5 mg)
until a maximum of 1.5 mg if the patient did not reach
85% of maximum HR with 30 mcg of dobutamine
(Figure 1).
T h ep r e s e n c eo fs y m p t o m sa n dt h eh e m o d y n a m i c
variables such as heart rate, blood pressure and diastolic
velocity in the LAD coronary artery were recorded in
each stage (Figure 2).
CFR was calculated as the ratio between peak diastolic
flow velocity and baseline diastolic flow velocity; final
values of flow velocity represented an average of 3 car-
diac cycles. As we have previously defined, abnormal
CFR was considered with a value < 2 according to pre-
vious invasive and non-invasive studies [12,14].
Results
Feasibility
CFR could be determined in 31/33 patients (Feasibility
94%).
Among the 31 patients in whom CRF could be mea-
sured, only one did not reach the normal reference
value (≥ 2)
Complications
No major complications were reported. One patient pre-
sented supraventricular tachycardia that reverted spon-
taneously when the infusion was stopped.
Hemodynamic variables
Mean arterial pressure (MAP) showed a small decrease
due to the effect of the drug; the other variables did not
present significant changes (Table 2). Intravenous atro-
pine was administered in 10 patients (30%) and 16
( 4 8 % )n e e d e d5 0m c g / k g / m i no fd o b u t a m i n et oc o m -
plete the study.
Wall motion analysis
Regional wall motion analysis was performed after digi-
tal image acquisition using a 16-segment model.
The test was negative for myocardial ischemia in all
patients as wall motion improved in all the territories
and systolic wall thickness increased.
Analysis of CFR
Coronary flow velocity increased from a mean value of
24.9 ± 7.11 cm/s at baseline to a peak value of 69.24 ±
20.132 cm/s. The mean CFR at the end of the dobuta-
mine test was 2.67 ± 0.62 (see table 2). A direct correla-
tion was observed between heart rate and flow velocity
in the LAD coronary artery with higher dose of dobuta-
mine (Figure 3).
Only one 83 year-old male patient with a recent nor-
mal perfusion study and left ventricular hypertrophy in
the echocardiogram did not reach a CFR ≥ 2.
Excluding this patient, we performed and independent
analysis of the delta HR and the percentage of maxi-
mum predicted heart rate that should be reached to
attain a CFR ≥ 2.
We found an excellent correlation between delta HR
(difference between baseline HR and maximum HR) and
the increase in the CFR (correlation coefficient 0.84). In
this sense, we found that when HR increased ≥ 50 bpm,
CFR was ≥ 2 in 97.2% of patients (CI 93-99.2%; p <
0.001) (Figure 4).
At the same time, we analyzed the percentage of max-
imum predicted heart rate necessary to attain a CFR ≥
2, and we found a correlation coefficient of 0.73. In
addition, 95.6% of patients reached 75% of their
Figure 1 Study protocol. CFV: Coronary Flow Velocity.
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(CI 91.1 - 99%) (Figure 5).
Only two patients failed to reach these limits. When
each patient was analyzed separately, one of them
reached a CFR > 2 in the last stage with a HR of 149
b p m( d e l t aH R :6 8b p ma n dp e r c e n t a g eo fm a x i m u m
predicted HR: 91%) and HR decreased in other
patient with dobutamine infusion of 30 mcg/kg/min;
this patient required intravenous atropine and 50
mcg/kg/min of dobutamine to attain an adequate
CFR.
Discussion
The estimation of CFR using the method we have uti-
lized is interesting due to its clinical and physiopatholo-
gical value [15].
D e s p i t ed i p y r i d a m o l ei sm o r es u i t a b l ef o rt h ea s s e s s -
ment of CFR [5,6], dobutamine is one of pharmacologic
agents most commonly used during stress echocardio-
graphy [16]. However; the simultaneous estimation of
CFR is not frequent in daily practice, with any of the
above drugs; probably, this might be due to the lack of
experience of echo-laboratories with this method,
besides a relatively longer duration of the test that is
not covered by health care programs.
Dobutamine exerts a complex effect on the coronary
arteries: heart rate and myocardial contractility increase
due to adrenergic stimulation, producing greater oxygen
(O2) uptake and reactive hyperemia [17]. The direct
effect of dobutamine produces vasodilatation by direct
effect on epicardial coronary arteries and microcircula-
tion (stimulation of b1, b2a n da adrenergic receptors
in the vascular wall) [18,19].
Dobutamine hyperemia is equivalent to adenosine-
induced vasodilatation in patients with ischemic
response to dobutamine, but lower than that observed
Figure 2 Flow velocity in the left anterior descending coronary artery. See the increase in peak velocity from 18.9 cm/s to 48.9 cm/s.
CFR: 2.6.
Table 2 Hemodynamic variables and ratio of flow velocities
VELOC (cm/seg) HR (bpm) Correlation with baseline flow in each stage % increase MAP (MmHg) % HR increase
Baseline 24.93 64 0.00 94.4
5 MCG 27.36 64.7 1.1 9.88 98.4 1.09375
10 MCG 31.1 69.6 1.3 24.90 98.9 8.75
20 MCG 38.9 81.2 1.5 56.22 99.5 26.875
30 MCG 46 99 1.8 84.74 93.3 54.6875
40 MCG 57.9 118 2.3 132.53 89.8 84,375
50 MCG 60.24 126.9 2.67 183.90 88.6 98.28125
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of dobutamine on CFR is lower than that of adenosine
according to studies using paired Doppler Flowires in
the catheterization laboratory [20,21].
In addition, dobutamine increases contractility and
myocardial O2 consumption, and produces release of
vasodilatory substances such as adenosine, which act on
epicardial arteries and microvasculature. Finally, dobuta-
mine, by increasing the heart rate, induces flow
mediated epicardial vasodilation [22,23].
The analysis of CFR has been studied in different clin-
ical scenarios; however there is little information about
coronary flow in each stage.
In a study performed at the Mayo Clinic by P. Pellikka
et al., the feasibility of assessing the CFR was 97% from
peak diastolic velocity. The authors concluded that CFR
assessment during dobutamine stress echocardiography
correlated well with wall thickening and detected is-
chemia early before development of wall motion
abnormality, emphasizing the importance of determining
CFR in this type of study [24].
We have not found any study analyzing and measur-
ing the relation between heart rate and coronary flow
reserve during this test.
In an excellent study, P. Meimoun et al. assessed CFR
during dobutamine stress echocardiography and com-
p a r e di tt ot h eC F Ro b t a i n e dw i t ha d e n o s i n ei nt h e
same group of patients and found a good correlation
and concordance between the tests, in a wide range of
LAD disease. Although a clear cut-off of heart rate was
not established in that study, it was emphasized along
the manuscript that a maximal achievable target heart
rate was necessary during dobutamine infusion to obtain
the good correlation and concordance between CFR-
dobutamine and CFR-adenosine. Furthermore, a signifi-
cant correlation was found in that study between CFR
during dobutamine and change of rate-pressure product
in patients with abnormal results [11].
In addition, the normal and abnormal values of CFR
during dobutamine stress were clearly described in that
study. A CFR < 2 with dobutamine stress echocardiogra-
phy was found in all patients who had a positive test in
the LAD territory (n = 8) and interestingly the same low
CFR < 2 was obtained with adenosine in these patients
[11].
Takeuchi et al. [10] studied 129 non selected patients.
In patients without wall motion abnormalities, mean
CFR was 2.76, similar to our findings. Coronary flow
velocity was evaluated in each stage, yet changes in
heart rate were not investigated.
It should be noted that the feasibility of analyzing CFR
during dobutamine stress (around 90%) according to our
previous experience and the results of previously men-
tioned studies [10,11] is a little lower compared to CFR
obtained using vasodilator agents (about 90-95%) [25].
Figure 3 Relation between HR and flow velocity in the left
anterior descending coronary artery.
Figure 4 Correlation between delta HR (max HR -baseline HR)
and Flow Velocity Ratio (FVR) in each stage of the test.R
0.8372 (95% CI 0.79-0.87) p < 0,001.
Figure 5 Correlation between % of predicted heart rate and
Flow Velocity Ratio (FVR) in each stage of the test. R 0.73 (95%
CI 0.65 - 0.79) p < 0,001.
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well as to the fact that, compared to dipyridamole,
dobutamine increases heart rate, myocardial contractility
and movements of the heart with displacement of the
LAD; for these reasons, the estimation of CFR may be
more difficult.
Finally, 97% patients achieved an adequate CFR with a
d e l t aH Ro f5 0b p mf r o mt h eb a s e l i n es t a g e .I nt h e
same sense, 95.6% of patients reached a normal CFR
with 75% of their predicted maximum heart rate.
This study puts in evidence that it is technically
recommended to obtain coronary artery flow in baseline
conditions and after reaching the predicted heart rate
(50 bpm greater than baseline HR or 75% of maximum
predicted HR) without forgetting about wall motion
response.
Clinical applications
The importance of this study is that there is no need to
measure CFR at each stage of the test; it can be deter-
mined at baseline and during high-dose of dobutamine
infusion if HR is 50 bpm greater compared to baseline
or has reached 75% of the maximum value predicted.
Further investigations are necessary to confirm the
added value of estimating CFR using dobutamine stress
echocardiography. Possibly, it may provide additional
information regarding mid- and long-term prognosis
besides increasing the sensitivity of the test as it has
been already demonstrated with dipyridamole [6,26].
Study limitations
The feasibility of the procedure might have been overes-
timated due to the relatively low number of patients
included and to the selection of patients with low pre-
test probability of coronary artery disease. However, as
this is a physiopathological study, the hemodynamic
data of the relation between drug dose, heart rate
attained and CFR are enough to draw conclusions.
CFR was only evaluated in the territory of the LAD cor-
onary artery as the feasibility of obtaining flow velocities
from the other coronary arteries is low due to increased
contractility secondary to dobutamine infusion.
As we did not perform coronary angiography in any
patient, some doubts may arise regarding the absence of
coronary artery lesions; yet the post-test probability was
enough to rule them out.
It should be taken into account that CFR may be
abnormal not only in lesions of the epicardial coronary
arteries but also in several conditions that modify base-
line coronary flow and its response to a stimulus. In this
sense, the analysis of the result is complex [27,28]. How-
ever, it is widely accepted that a normal value (≥ 2) rules
out a significant lesion in the territory evaluated
[6,14,29].
The fact that only beta-blockers, and no other medical
therapy, were withdrawn before dobutamine infusion
could have had some hemodynamic influence [30].
We did not use contrast agents which could have
improved the visualization of the LAD coronary artery
[31].
Conclusions
It is extremely important to reach a delta HR of at least
50 bpm or a HR of at least 75% of the maximum pre-
dicted heart rate to consider abnormal a CFR value.
The feasibility of determining CFR in the territory of
the LAD during dobutamine stress echocardiography
was high.
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